ArticleVaccines2025
Deficits in Long-Term Vaccine Immunity Among Childhood Cancer Survivors Despite Revaccination Programs.
Article in Vaccines, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundChildhood cancer survivors (CCSs) often experience impaired humoral immunity because of cancer treatments that increase their susceptibility to vaccine-preventable diseases. This study aimed to assess the seroprevalence of tetanus and rubella antibodies in CCSs compared to healthy, age-matched controls. Additionally, we explored the impact of cancer treatments on vaccine-induced immunity, examined the extent of revaccination after treatment completion, and evaluated the effectiveness of revaccination on seroprevalence.
methodsThis retrospective study included 180 CCSs previously treated at Astrid Lindgren Children's Hospital, Stockholm, between March 2019 and January 2023. Patient data were retrieved from electronic medical records. Seroprevalence data for rubella and tetanus antibodies in the 15-19-year age group were also obtained from a national seroprevalence study conducted by the Public Health Agency of Sweden.
resultsCCSs exhibited significantly lower seroprevalence for both tetanus (77.7% vs. 92.7%) and rubella (79.1% vs. 97.5%) compared to age-matched controls. Revaccination with DTP-containing vaccines was more frequently administered than with the MMR vaccine. Tetanus and rubella seroprevalence were the lowest in children who had received intense chemotherapy. Among those who were revaccinated with the DTP vaccine after intensive treatment, 81 out of 98 (82.6%) had tetanus IgG levels above the threshold, compared to 24 out of 48 (50%) unvaccinated CCSs. In contrast, among those revaccinated with MMR, 57 out of 73 (78.1%) had positive rubella IgG, compared to 53 out of 73 (72.6%) unvaccinated CCSs with rubella IgG levels above the cut-off.
conclusionsOur findings highlight that vaccines are underutilized in CCSs with a notable gap in immunity, particularly among those who have undergone intensive treatments. Unexpectedly, MMR revaccination did not significantly affect rubella immunity. Given the increasing number of CCSs, it is essential to better understand how to effectively restore vaccine immunity in this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.